4.4 Article

Does Weight Impact Anidulafungin Pharmacokinetics?

Journal

CLINICAL PHARMACOKINETICS
Volume 55, Issue 10, Pages 1289-1294

Publisher

ADIS INT LTD
DOI: 10.1007/s40262-016-0401-8

Keywords

-

Funding

  1. Pfizer, Inc.

Ask authors/readers for more resources

Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index > 40 kg/m(2)). Anidulafungin exposure was on average 32.5 % lower compared with the general patient population, suggesting dose increases may be required in this population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available